Stott H, Fox W, Girling D J, Stephens R J, Galton D A
Br Med J. 1977 Dec 10;2(6101):1513-7. doi: 10.1136/bmj.2.6101.1513.
During a double-blind study of two years' cytotoxic chemotherapy with busulphan or cyclophosphamide in patients who had had resection of carcinoma of the bronchus the long-term effects of these two drugs were also studied. Four of the 243 patients treated with busulphan developed leukaemia compared with none of the 234 treated with cyclophosphamide and none of the 249 on placebo. None of these four patients received radiotherapy or other cytotoxic chemotherapy before leukaemia was diagnosed, and all four were among the 19 patients who developed pancytopenia while taking busulphan, five to eight years before leukaemia became clinically apparent. These findings suggest that busulphan is leukaemogenic, though its mode of action is uncertain.
在一项针对支气管癌切除术后患者使用白消安或环磷酰胺进行为期两年的双盲细胞毒性化疗研究中，还对这两种药物的长期影响进行了研究。接受白消安治疗的243名患者中有4人患白血病，而接受环磷酰胺治疗的234人以及接受安慰剂治疗的249人中均无人患白血病。这4名患者在白血病被诊断之前均未接受过放疗或其他细胞毒性化疗，且这4人都在服用白消安期间出现全血细胞减少的19名患者之中，白血病在临床上显现出来的五至八年前就出现了全血细胞减少。这些发现表明白消安具有致白血病作用，尽管其作用方式尚不确定。
